Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

15.98 +0.21 (+1.33%)
Streaming Delayed Price Updated: 3:31 PM EDT, May 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Aurinia Pharmaceuticals: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Why Aurinia Pharmaceuticals Stock Is Glowing Green Today ↗
Investors appear to be cheering another patent win by the company. 
Via The Motley Fool
News headline image
Aurinia Pharmaceuticals's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Aurinia Announces 2023 Annual General Meeting Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Preview: Aurinia Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
Tesla, AMD, Ford, Starbucks, Aurinia Pharma: Why These 5 Stocks Are Drawing Investors' Attention Today ↗
 
Via Benzinga
News headline image
ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General Meeting
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Glass Lewis Recommends Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual Meeting
From Aurinia
Via Business Wire
News headline image
3 Biotechs That Might Get Bought Out in 2023 ↗
Biotech is expected to be a hotbed of mergers and acquisitions this year. 
Via The Motley Fool
News headline image
Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Second Quarter Outlook For Biotech Stocks ↗
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. 
Via Talk Markets
News headline image
Is Aurinia Pharmaceuticals Up for Grabs? Shareholder Suggests a Quick Sale for a Bigger Payday ↗
 
Via Benzinga
News headline image
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
3 Stocks That Already Doubled in 2023 and Could Keep Climbing ↗
The gains these stocks notched in the first few months of the year could be the beginning of a much longer bull run. 
Via The Motley Fool
News headline image
What's Going On With Aurinia Pharmaceuticals Stock Wednesday? ↗
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher Wednesday after the company announced "promising results" from its AURORA 
Via Benzinga
News headline image
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
What's Going On With Aurinia Pharmaceuticals Stock Today? ↗
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares are trading higher after the company reported better-than-expected fourth-quarter EPS and sales fig 
Via Benzinga
News headline image
Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.